It is made available under a CC-BY-NC-ND 4.0 International license .

1 Plasmodium vivax malaria serological exposure markers: assessing the degree 2 and implications of cross-reactivity with P. knowlesi Rhea J Longley^{1,2*}, Matthew J Grigg³, Kael Schoffer¹, Thomas Obadia^{4,5}, Stephanie 3 Hyslop¹, Kim A. Piera³, Narimane Nekkab⁴, Ramin Mazhari^{1,2}, Eizo Takashima⁶, 4 Takafumi Tsuboi⁶, Matthias Harbers^{7,8}, Kevin Tetteh⁹, Chris Drakeley⁹, Chetan E. 5 Chitnis¹⁰, Julie Healer^{1,2}, Wai-Hong Tham^{1,2}, Jetsumon Sattabongkot¹¹, Michael T 6 White⁴, Daniel J Cooper^{3,12}, Giri S Rajahram¹³, Bridget E. Barber³, Timothy 7 William^{14,15}, Nicholas M Anstev³, Ivo Mueller^{1,2} 8 9 ¹Population Health and Immunity Division, WEHI, Parkville 3052, Australia. 10 ²Department of Medical Biology, University of Melbourne, Parkville 3052, Australia. 11 ³Menzies School of Health Research and Charles Darwin University, Darwin, NT, 12 Australia. 13 ⁴Institut Pasteur, Université de Paris, Infectious Disease Epidemiology and Analytics 14 G5 Unit, F-75015, Paris, France. 15 ⁵Institut Pasteur, Université de Paris, Bioinformatics and Biostatistics Hub, F-75015. 16 17 Paris. France. ⁶Division of Malaria Research, Proteo-Science Center, Ehime University, 18 Matsuyama, Japan. 19 ⁷CellFree Sciences Co., Ltd., Yokohama, Japan. 20 ⁸RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. 21 ⁹London School of Hygiene and Tropical Medicine, London, United Kingdom. 22 ¹⁰Malaria Parasite Biology and Vaccines Unit, Department of Parasites and Insect 23 24 Vectors, Institut Pasteur, Paris. ¹¹Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, 25 Bangkok, Thailand. 26 ¹²Department of Medicine, University of Cambridge, Cambridge, UK. 27 ¹³Queen Elizabeth II Hospital, Clinical Research Centre, Kota Kinabalu, Sabah, 28 Malaysia. 29 ¹⁴Infectious Diseases Society Kota Kinabalu Sabah, Kota Kinabalu Sabah, Malaysia. 30 31 ¹⁵Gleneagles Hospital, Kota Kinabalu, Sabah, Malaysia. 32 33 *email: Longley.r@wehi.edu.au 34 35 Short title: Plasmodium cross-species immune reactivity 36 37

It is made available under a CC-BY-NC-ND 4.0 International license .

38 Summary

39 Serological exposure markers are a promising tool for surveillance and targeted 40 interventions for *Plasmodium vivax* malaria. P. vivax is closely related to the zoonotic 41 parasite P. knowlesi, which also infects humans. P. vivax and P. knowlesi are co-42 endemic across much of South East Asia, making it important to design P. vivax 43 serological markers that minimise cross-reactivity in this region. Our objective was to 44 determine the degree of IgG antibody cross-reactivity against a panel of P. vivax 45 serological markers in samples from human participants with *P. knowlesi* malaria. We 46 observed higher levels of IgG antibody reactivity against P. vivax proteins that had 47 high levels of sequence identity with their P. knowlesi ortholog. IgG reactivity peaked 48 at 7 days post P. knowlesi infection and was short-lived, with minimal responses 49 detected at 1-year post-infection. Using these data, we designed a panel of 8 P. vivax 50 proteins with low-levels of cross-reactivity with P. knowlesi. This panel was able to 51 accurately classify recent P. vivax infections whilst reducing misclassification of 52 recent P. knowlesi infections.

It is made available under a CC-BY-NC-ND 4.0 International license .

54 Introduction

55 In order to accelerate towards malaria elimination, new tools and interventions are 56 needed. Malaria is caused by the parasite *Plasmodium*, with the majority of disease in 57 humans caused by P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi. P. 58 falciparum and P. vivax account for the largest burdens of disease. In many co-59 endemic regions outside Africa, infection with P. vivax has become the predominant 60 cause of malaria as the overall level of transmission has declined (reviewed in¹). 61 Thus, whilst standard malaria control tools (such as those targeting the mosquito 62 vector and case management) have had a significant impact on reducing transmission 63 of *P. falciparum*, they have not had the same level of effect on *P. vivax*. This is most 64 likely due to a number of distinct biological features of *P. vivax* infections that 65 promote transmission. These include a cryptic endosplenic life-cycle leading to a large hidden splenic reservoir of P. vivax parasites^{2,3} which sustains a high prevalence 66 of low-density asymptomatic blood stage infections⁴ that are still capable of onward 67 transmission⁵. Furthermore, an additional life-cycle stage in the liver, known as the 68 69 hypnozoite, can remain arrested or dormant in the liver for months to years following 70 the initial mosquito-bite induced infection, before being reactivated by currently 71 unknown signals to re-join the life-cycle. Hepatic hypnozoites are major reservoirs for 72 transmission in communities, with up to 80% of detected blood-stage infections attributed to hypnozoite relapse rather than new mosquito bite-induced infections⁶⁻⁸. 73

74

To address the unique challenge to malaria elimination posed by *P. vivax*, we have developed a novel surveillance tool: *P. vivax* serological exposure markers. By measuring total IgG antibody responses to a carefully selected panel of 8 *P. vivax* proteins, we can classify individuals as recently exposed to a blood-stage *P. vivax*

It is made available under a CC-BY-NC-ND 4.0 International license .

infection within the past 9-months with 80% sensitivity and 80% specificity⁹. Due to 79 the frequency of *P. vivax* relapses¹⁰, we hypothesize our *P. vivax* serological exposure 80 81 markers can be used to indirectly identify hypnozoite carriers – individuals who are 82 more likely to go on to develop recurrent P. vivax infections. Our serological markers 83 can thus be used as an effective surveillance tool for identifying clusters of P. vivax infections for efficient targeting of resources¹¹, and for designing public health 84 interventions relying on "serological testing and treatment" (seroTAT)¹². SeroTAT 85 86 can be used to identify hypnozoite carriers who can then be treated with appropriate 87 anti-malarial drugs (including an anti-liver stage component such as primaguine or 88 tafenoquine) as part of an elimination campaign⁹.

89

90 The major species of *Plasmodium* causing disease in humans have different geographic distributions¹³ and different levels of relatedness¹⁴. It is therefore 91 92 important to characterise potential cross-reactivity against our P. vivax serological 93 exposure markers in individuals who have had recent exposure to other *Plasmodium* 94 infections. We identified no patterns of cross-reactivity with recent P. falciparum 95 exposure in our original cohort studies⁹, with the caveat that few individuals had P. 96 falciparum infections in those observational cohorts (in Thailand, Brazil and the 97 Solomon Islands). In the limited number of prior studies assessing P. vivax - P. falciparum cross-reactive antibody responses¹⁵, mixed results were observed with 98 both species-specific¹⁶ and cross-reactive antibodies detected^{17,18}. However, even if 99 100 cross-reactivity between our P. vivax proteins in individuals with recent P. falciparum 101 infections becomes evident, this is not necessarily of programmatic concern. Similar 102 risk-factors for exposure in co-endemic regions are present and there is potential 103 benefit in treating individuals with P. falciparum infections with anti-hypnozoite

It is made available under a CC-BY-NC-ND 4.0 International license .

drugs¹⁹ (due to the high risk of *P. vivax* recurrence following *P. falciparum* 104 infections²⁰⁻²²). P. vivax is more closely related to the zoonotic parasite P. knowlesi 105 than P. falciparum¹⁴ and serological cross-reactivity has been reported²³⁻²⁵. P. vivax 106 107 and P. knowlesi are co-endemic in humans across much of South East Asia²⁶. Riskfactors for exposure to P. knowlesi and P. vivax also differ²⁷, as do spatial clusters of 108 infections²⁵, treatment²⁸ and risk mitigation strategies²⁷. For these reasons, and to 109 110 optimise the utility of serological markers in South East Asia, it is of particular 111 importance to characterise cross-reactivity against the *P. vivax* serological exposure 112 markers in individuals with recent P. knowlesi infections.

113

Here, we aimed to assess cross-reactivity against a panel of *P. vivax* serological exposure markers (including our previously identified top combination of 8 markers⁹) in samples from two clinical cohorts of patients with confirmed *P. knowlesi* malaria. We assessed whether our algorithm would classify these *P. knowlesi* patients as *P. vivax*-exposed or not, and whether we could improve our serological markers for use in *P. vivax-P. knowlesi* co-endemic areas by selecting proteins with absent or lower levels of cross-reactivity.

121

```
122 Results
```

123

124 Comparison of *P. vivax* and *P. knowlesi* protein sequences

We hypothesized that potential antibody cross-reactivity could relate to the level of sequence identity and thus we first constructed a pipeline to identify and then compare the sequences of our *P. vivax* serological exposure markers with their identified *P. knowlesi* orthologs. Two different analytical approaches were used: 1) by

129	accessing the list of orthologs on PlasmoDB for each P. vivax protein and 2) through
130	a NCBI BlastP search of the protein sequence construct. P. knowlesi orthologs were
131	found for 17 of 21 P. vivax proteins via PlasmoDB (using either the original macaque
132	H strain ²⁹ or the later human red blood cell adapted A1H1 line ³⁰) and for 20/21 by
133	NCBI BlastP (any strain) (Table 1). Using both methods each of the 21 P. vivax
134	proteins had at least one identified P. knowlesi ortholog. When multiple orthologs
135	were found, the top hit was selected by highest identity. The similarity and identity
136	values for the hits on PlasmoDB were obtained by aligning the full-length protein
137	sequences provided in the database using the EMBOSS Needle protein alignment
138	tool; the identity values for the NCBI BlastP hits were obtained from the BlastP
139	search using only the protein construct sequence. The sequence identity of the full-
140	length protein sequences (search strategy 1) ranged from 11-19% for MSP7F (A1H1
141	line or H strain, respectively) to 83.4% for MSP8. A similar trend was found using the
142	specific protein construct and NCBI BlastP (search strategy 2) however the percent
143	identity was often higher using this method (Table 1).

144 Table 1: Sequence comparison of the *P. vivax* proteins with their *P. knowlesi* orthologs. Full-length protein sequences were first compared 145 using the orthologs listed in the PlasmoDB database, then the protein construct sequences were compared using NCBI BlastP to identify the top 146 hits (see Table S1 for the amino acid region of each construct). NA indicates there were no matches for the database search. Proteins are ordered 147 by highest percentage sequence identity using the NCBI BlastP method. The H strain and A1H1 line gave identical results except for MSP7F; 148 the H strain results are listed, A1H1 gave 11.5% identity and 18.8% similarity. * Indicates top 8 *P. vivax* protein serological exposure marker.

P. vivax		P. knowlesi							
			Plasmo		NCBI (any strain)				
P. vivax Protein	PlasmoDB code	# Hits	Top Hit	Synteny	Similarity (%)	Identity (%)	Top Hit	Identity (%)	
MSP8 *	PVX_097625	1	PKNH_1031500	Y	91.2	83.4	AFL93300.1	84.52	
Pv-fam-a*	PVX_112670	24	PKNH_1300800	Y	72.8	65.8	OTN66803.1	83.11	
MSP1-19*	PVX_099980	1	PKNH_0728900	Y	74.4	64.2	AZL87433.1	81.31	
RAMA*	PVX_087885	0	NA	NA	NA	NA	<u>OTN68698.1</u>	73.61	
RIPR	PVX_095055	1	PKNH_0817000	Y	82.9	71.9	<u>XP_002258810.1</u>	73.43	
Pv-fam-a*	PVX_096995	24	PKNH_0200900	Y	50.9	41.1	<u>OTN66147.1</u>	70.28	
PTEX150	PVX_084720	1	PKNH_0422900	Y	83.9	73.2	<u>OTN66840.1</u>	72.02	
DBPII Sal 1	PVX_110810	3	PKNH_0623500	Y	64.7	52.1	<u>OTN68355.1</u>	68.72	
DBPII AH	AAY34130.1	3	PKNH_0623500	Y	64.7	51.9	<u>OTN68355.1</u>	68.21	
Sexual stage antigen s16	PVX_000930	1	PKNH_0304300	Y	78.6	67.1	<u>OTN68464.1</u>	65.45	
TRAP	PVX_082735	1	PKNH_1265400	Y	81.4	69.1	<u>AAG24613.1</u>	64.23	
MSP3b	PVX_097680	15	PKNH_1457400	Ν	42	28.6	<u>OTN63878.1</u>	62.5	
MSP5	PVX_003770	2	PKNH_0414200	Y	65.4	49.9	<u>AAT77929.1</u>	46.26	
Hypothetical	PVX_097715	0	NA	NA	NA	NA	<u>ANP24393.1</u>	40.65	
EBP region II*	KMZ83376.1	0	NA	NA	NA	NA	<u>QPL17772.1</u>	35	
RBP2b ₁₉₈₆₋₂₆₅₃	PVX_094255	2	PKNH_0700200	Ν	52.2	29.1	<u>OTN67427.1</u>	34.53	
MSP7F	PVX_082670	15	PKNH_0726500	Ν	30.1	19	AND94835.1	27.53	
RBP2b ₁₆₁₋₁₄₅₄ *	PVX_094255	2	PKNH_0700200	Ν	52.2	29.1	<u>OTN67427.1</u>	26.1	
RBP2a	PVX_121920	2	PKNH_0700200	N	46.7	25.4	<u>OTN67427.1</u>	25.77	
MSP7L	PVX_082700	0	NA	NA	NA	NA	AND94835.1	24.29	
MSP3a*	PVX_097720	15	PKNH_1457400	N	45.8	31.6	NA	NA	

It is made available under a CC-BY-NC-ND 4.0 International license .

149 P. vivax protein-specific IgG antibody response in P. knowlesi clinical case

150 samples

151 To assess potential cross-reactivity against the P. vivax proteins we measured 152 longitudinal total IgG antibody responses in patients with PCR-confirmed P. knowlesi 153 monoinfection, enrolled in two clinical trials, denoted ACTKNOW (recruited over 2012-2014³¹) and PACKNOW (recruited over 2016-2018³²) (Table 2). The two 154 155 sample sets were initially analysed separately given the risk of prior P. vivax infection 156 was lower at the time of the PACKNOW trial³³. There were no differences in 157 demographic variables such as age, sex and self-reported history of malaria infections 158 between the patients in the two trials (Table 2).

160	Table 2: Characteristics	of patients in two P	knowlesi clinical trial	l cohorts used in the current study	y.
-----	--------------------------	----------------------	-------------------------	-------------------------------------	----

	ACTKNOW (n=99)	PACKNOW (n=41)
PCR-confirmed Plasmodium spp.	P. knowlesi	P. knowlesi
Collection year	2012-2014	2016-2018
Age (years), median (range) ^a	34 (3-78)	36 (20-70)
Sex, number female ^b (percent)	29 (29.3%)	6 (14.6%)
Self-reported fever days, median (range) ^a	5 (0-14)	4 (3-14)
Self-reported previous malaria infection, number yes ^b	34 (34.3%)	17 (41.5%)
(percent)		
Parasitaemia (parasites/µl), median (range) ^a	2857 (56-43,721)	2690 (37-185,553)
Treatment administered	Randomised to artesunate-mefloquine	Artemether-lumefantrine
	(n=52) or chloroquine (n=47)	
Serology details		
Sample size at enrolment	99	41
Follow-up timepoints	3: day 0, 7, 28	5: day 0, 7, 14, 28, 365
Total # samples assessed	296 ^c	166 ^d

^aStatistical difference between ACTKNOW and PACKNOW cohorts assessed by Mann-Whitney test, not significant. ^bStatistical difference

162 between ACTKNOW and PACKNOW cohorts assessed by Fisher's exact test, not significant. ^cOne sample missing serology data at day 0.

163 ^dSamples were not available at all time-points for all patients.

164

It is made available under a CC-BY-NC-ND 4.0 International license .

165 We first assessed potential cross-reactivity against the *P. vivax* proteins using 99 166 patients from the ACTKNOW P. knowlesi clinical trial cohort, with plasma samples 167 available at the time of diagnosis of *P. knowlesi* infection (day 0) and follow-up at 168 day 7 and day 28. Median parasitemia prior to treatment (day 0) was 2,857 169 parasites/ μ L (IQR 648-7,177), with all subjects negative for asexual stage parasites and 95% negative for sexual stages by the day 7 timepoint³¹. Antibody responses 170 171 were compared to malaria-naïve negative control samples from the non-endemic 172 cities of Melbourne, Australia, Bangkok, Thailand and Rio, Brazil (n=369), with a 173 protein-specific seropositivity cut-off defined as the average of the negative controls 174 plus two times the standard deviation. We observed an increase in the median IgG 175 antibody response against all P. vivax proteins at day 7 compared to day 0, with IgG 176 levels declining from the peak response by day 28 (Fig. 1). For 17 of 21 P. vivax 177 proteins, median IgG levels at day 7 (the peak of the response) were above the sero-178 positivity cut-off. Of those 17 proteins, for five the median IgG level had dropped 179 below the sero-positivity cut-off by day 28. For all *P. vivax* proteins there were at 180 least some patients with responses above the sero-positivity cut-off at all three time-181 points (see Supplementary Figure 1 for the change in IgG levels at the individual level 182 over time, n=98 patients with matched data from all three time-points). We explored 183 whether acquisition of cross-reactive IgG antibodies at day 0 was related to delayed 184 presentation to the clinic (and therefore delayed enrolment into the study), using 185 duration of fever as a surrogate for delayed presentation/duration of infection. There 186 was no correlation between day 0 IgG antibodies and duration of fever for 19/21 P. 187 vivax proteins; there was a weak negative correlation for both DBPII constructs 188 (Spearman correlation, AH r=-0.25, Sal1 r=-0.2, p<0.05 see Figure S2). The highest 189 levels of potential cross-reactivity were observed for MSP1-19, MSP8, Pv-fam-a

medRxiv preprint doi: https://doi.org/10.1101/2021.12.09.21266664; this version posted December 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

190 (PVX_096995) and RAMA, with median IgG levels at day 7 greater than 10-fold 191 compared to the seropositivity cut-off. All 4 of these proteins are used in the 192 classification algorithm based on a combination of antibody responses to 8 proteins, 193 with MSP1-19 and RAMA particularly having an important contribution to the 194 classification performance based on a variable importance plot⁹.

195



196

197 Fig. 1. IgG antibody levels against 21 P. vivax proteins in patients with clinical P. 198 knowlesi infections. IgG levels were measured against the 21 P. vivax proteins using 199 a multiplexed antibody assay. Individual patients (n=99) had longitudinal samples 200 obtained and run at the time of diagnosis of *P. knowlesi* infection (day 0), and days 7 201 and 28 following enrolment (ACTKNOW cohort). Day 0 has data from 98 samples due to the wrong sample being re-run following quality control. Results are expressed 202 203 as the relative antibody units (RAU). Proteins are ordered by highest level of median 204 IgG at day 7 compared to the seropositivity cut-off. Dashed lines indicate the malaria-205 naïve negative control samples: orange = average of the negative control samples; 206 blue = seropositivity cut-off (average plus 2x standard deviation).

It is made available under a CC-BY-NC-ND 4.0 International license .

208

209 In order to confirm the results of the ACTKNOW study and to determine the 210 longevity of the cross-reactive antibody response over 1 year (median 369 days; IQR 211 365-394) post P. knowlesi-infection, we measured IgG antibody levels against the 21 212 *P. vivax* proteins in the PACKNOW clinical trial cohort samples (n=41 patients with 213 up to 5 time-points available, recruited over 2016-2018, at a time of near-elimination 214 of *P. vivax* in Sabah). These patients were all treated with artemether-lumefantrine. 215 Median parasitemia prior to treatment (day 0) was 2,690 parasites/µL (IQR 572-216 14,317), with all subjects negative for asexual stage parasites by the day 7 217 timepoint³². There was no significant difference in parasitaemia at day 0 between the 218 ACTKNOW and PACKNOW subjects (median 2857 vs 2690 respectively, see Table 219 2). Similar to the ACTKNOW cohort, we observed a peak in the total IgG response to 220 all 21 P. vivax proteins at days 4-15 post enrolment, with responses generally 221 declining by the day 27-30 time-point (Fig. 2). Total IgG antibodies against the 222 protein *P. vivax* MSP1-19 were an exception, with elevated levels maintained at the 223 day 27-30 time-point and also at 1-year. By 1-year after P. knowlesi infection, the 224 median P. vivax total IgG antibodies had declined to below the sero-positivity cut-off 225 for all other proteins (Fig. 2). There were fewer *P. vivax* proteins (n=11/21) with a 226 peak median total IgG response above the sero-positivity cut-off in the PACKNOW 227 samples (collected across 2016-2018) compared to the ACTKNOW samples 228 (collected across 2012-2014) (n=17/21), although this was not statistically significant 229 (Fisher's exact test, p=0.1). There was a significantly higher magnitude total IgG 230 response to 9/21 P. vivax proteins in the ACTKNOW compared to PACKNOW 231 cohorts at day 7 (Mann-Whitney U test, see Figure S3). The top 4 P. vivax proteins 232 with the highest levels of cross-reactivity evident were the same as the ACTKNOW

- 233 cohort, being MSP1-19, MSP8, Pv-fam-a (PVX_096995) and RAMA (median IgG
- 234 levels at day 7 more than 6-fold higher than the sero-positivity cut-off).



Figure 2: IgG antibody levels against 21 *P. vivax* proteins in patients up to 1 year post clinical *P. knowlesi* infections. IgG levels were measured against the 21 *P. vivax* proteins using a multiplexed antibody assay. Samples were obtained and run at the time of *P. knowlesi* infection (day 0) (n=41), days 4-9 (n=35), days 10-15 (n=15), days 27-30 (n=33) and days 339-444 (n=42) following enrolment (PACKNOW cohort). Results are expressed as the relative antibody units (RAU). Proteins are ordered as per Figure 1. Dashed lines indicate the malaria-naïve negative control complex orange – expressed of the protein complex blue – compositivity out off (current plue 2) off (current plue 2).

control samples: orange = average of the negative control samples; blue = seropositivity cut-off (average plus 2x standard deviation).

242

236

It is made available under a CC-BY-NC-ND 4.0 International license .

There was a statistically significant correlation between the fold change comparing the median IgG level at the peak at day 7 with the seropositivity cut-off and the percentage sequence identity of the *P. knowlesi* and *P. vivax* orthologs for both the ACTKNOW and PACKNOW cohorts (Fig. 3A-B) (Spearman correlation, r=0.63, p=0.0023 and r=0.56, p=0.0083, respectively) and using median IgG antibody data from both patient cohorts combined (r=0.69 p=0.0006, Fig. 3C).

249



250

251 Fig. 3. Correlation between the peak anti-P. vivax IgG level at day 7 and the 252 percentage sequence similarity of the P. vivax and P. knowlesi orthologs. The 253 median IgG level at day 7 (the peak of the response) was divided by the seropositivity 254 cut-off to generate the fold change at the peak compared to the background. The 255 percentage sequence identity was calculated for the protein construct sequence (not 256 full-length for all proteins) using NCBI BlastP. Where there was no hit for NCBI 257 BlastP the PlasmoDB method was used (see Table 1). A Spearman's correlation was 258 performed to determine the relationship of the fold change with the sequence identity 259 using data from all 21 *P. vivax* proteins, for the A) ACTKNOW r=0.63 p=0.0023, B) 260 PACKNOW cohorts r=0.56 p=0.0083 and C) ACTKNOW and PACKNOW 261 combined (median antibody level of n=134 *P. knowlesi* patients at Day 7 divided by 262 the seropositivity cut-off) r=0.69 p=0.0006.

263

264 Classification of recent exposure to P. vivax blood-stage infections in the P.

265 knowlesi cohorts

As high levels of cross-reactivity (>6-10 fold increase over the sero-positivity cut-off)

- 267 were evident between four of our top 8 P. vivax proteins in the two series of P.
- 268 knowlesi clinical case samples (MSP1-19, MSP8, Pv-fam-a (PVX_096995), RAMA),

It is made available under a CC-BY-NC-ND 4.0 International license .

269 we next used these data in our previously developed classification algorithm to 270 determine whether any of the samples from patients with current or recent P. knowlesi 271 infections were classified as recently exposed to P. vivax. The top 8 P. vivax proteins 272 used in the classification algorithm are: MSP1-19, MSP8, Pv-fam-a (PVX_096995), 273 RAMA, RBP2b₁₆₁₋₁₄₅₄, Pv-fam-a (PVX_112670), MSP3a, and EBP. We utilised a 274 balanced sensitivity and specificity target of 79%. We ran the algorithm on both the 275 ACTKNOW and PACKNOW cohorts at all time-points for which we had data, and 276 the proportion of patients classified as positive by the algorithm varied between 17-277 82% (Table 3). The trend was for the highest numbers of *P. knowlesi* patients to be 278 classified as recently exposed to P. vivax at the day 7 timepoint in both cohorts (82% 279 ACTKNOW, 77% PACKNOW), in line with the highest peak IgG activity. The 280 lowest proportion of P. knowlesi patients classified as positive was for the 281 PACKNOW cohort at Day 365 (7/42, 17%).

282

283 For the ACTKNOW cohort, of the 99 patients, 46 were classified positive by the 284 algorithm at all three time-points. 20 were classified positive at day 7 and day 28, 14 285 at day 7 only, two at day 28 only and one at day 0 and day 7. 16 patients were not 286 classified as positive at any timepoint. Whilst there was variability in the available 287 plasma samples post enrolment for the PACKNOW cohort, 9 patients were not 288 classified positive at any timepoint and all those who were positive at a later 289 timepoint (day 28 or day 365) were previously positive for at least one of the earlier 290 timepoints (i.e. day 0, 7 or 14). The exceptions were 1 patient who was positive at 291 only day 28 and 1 patient positive at only day 365 (the latter had notably high 292 antibody levels at day 365, reaching equivalent to a 1/50 dilution of the positive 293 control pool against 4 of 8 antigens).

It is made available under a CC-BY-NC-ND 4.0 International license .

204	
294	

295 Table 3: Output from *P. vivax* classifier using IgG antibody responses from top 8

296 *P. vivax* serological exposure markers. A balanced 79% specificity, 79% sensitivity

297 target was used.

Samples	Total number	Classified Positive	Percent Positive (%)
	(n)	(n)	
ACTKNOW			
Day 0	98	47	48.0
Day 7	99	81	81.8
Day 28	99	68	68.7
PACKNOW			
Day 0	41	21	51.2
Day 7	35	27	77.1
Day 14	15	11	73.3
Day 28	33	20	60.6
Day 365	42	7	16.7

298

299 Design and application of an adjusted *P. vivax*-specific serological marker panel

300 In both the ACTKNOW and PACKNOW *P. knowlesi* clinical cohorts, more than half 301 the patients at day 7 and day 28 post-infection were classified as recently exposed to 302 P. vivax blood-stage parasites using our existing algorithm with our set of 8 P. vivax 303 serological exposure markers. This indicated our current serological exposure marker 304 panel was not P. vivax-specific. We hypothesized that using proteins with low-levels 305 of cross-reactivity in the P. knowlesi infected patients would reduce misclassification. 306 We thus designed a new panel of 8 *P. vivax* serological exposure markers by selecting 307 the proteins with the lowest levels of cross-reactivity in the P. knowlesi clinical 308 samples (as determined by the median IgG level at Day 7 from the ACTKNOW 309 sample set compared to the background, as described for Fig. 3). These proteins were: 310 RBP2b₁₉₈₆₋₂₆₅₃, MSP7L, MSP7F, TRAP, DBPII Sal1, hypothetical (PVX_097715), 311 sexual stage antigen s16, and EBP (all with a fold change of less than 2). DBPII AH 312 was not selected given this is a variant of the DBP region II that was already included 313 (Sal1 strain included). We re-trained the algorithm on our existing Thai, Brazilian and

It is made available under a CC-BY-NC-ND 4.0 International license .

314 Solomon Islands datasets⁹ for these 8 P. vivax proteins. Youden's J was used to 315 determine the best trade-off balancing sensitivity and specificity, assuming equal 316 importance of false positives and false negatives in the classification process. The 317 algorithm trained with the new panel of 8 *P. vivax* proteins achieved 72.4% sensitivity 318 and 70.8% specificity respectively, for classifying recent P. vivax infections within 319 the prior 9-months (Fig. 4A). When applied to confirmed P. knowlesi clinical cases, 320 we identified a reduced number of 210/462 (45%) samples being classed as recently 321 exposed to P. vivax (Table 4) (compared to 281/462 (61%) using the original panel). 322 Misclassification was still high at day 7 post-P. knowlesi infection (69.7% 323 ACTKNOW and 80% PACKNOW) but less than 58% at day 28 and 7% at day 365. 324 The greatest reduction in numbers and proportions of *P. knowlesi* patients classified 325 positive by the algorithm was for the ACTKNOW cohort.

326

327 Whilst the new combination of 8 P. vivax proteins reduced overall misclassification of 328 P. knowlesi clinical cases, the sensitivity and specificity for correctly classifying 329 recent P. vivax infections (72.4%, 70.8%) was substantially lower than the original 8 330 $(80\% \text{ for both}^9)$. We hypothesized this was because the new panel did not include the top classifier RBP2b₁₆₁₋₁₄₅₄ (see Fig. 4. and Longley, White et al., 2020⁹). As this 331 332 protein also had relatively low-levels of cross-reactivity in the P. knowlesi samples at 333 day 7 (fold change 2.9 compared to the seropositivity cut-off), we replaced 334 RBP2b₁₉₈₆₋₂₆₅₃ in the new panel with RBP2b₁₆₁₋₁₄₅₄. This improved classification of 335 recent P. vivax infections in the Thai, Brazilian and Solomon Islands datasets to 336 78.7% sensitivity and 76.9% specificity (Fig. 4B), which is more comparable to the 337 original classifier. Applying this trained classification algorithm to the P. knowlesi 338 sample sets resulted in 215/462 (47%) samples being misclassified (Table 4), which is

It is made available under a CC-BY-NC-ND 4.0 International license .

less than when using the original algorithm (281) and similar to the 210 misclassified when using RBP2b₁₉₈₆₋₂₆₅₃ in the new panel (new algorithm RBP2b₁₉₈₆₋₂₆₅₃ vs RBP2b₁₆₁₋₁₄₅₄ P=0.79, Fisher's exact test). At day 7 post-*P. knowlesi* infection 68-71% were classified as recently exposed to *P. vivax*, reducing to 42-50% at day 28 and 10% at day 365. Those patients positive at day 365 were also classified positive at earlier timepoints.



346 347 Fig. 4. Classification of recent *P. vivax* infections using an adjusted *P. vivax* 348 antigen panel. Receiver operator characteristic curve for classifying individuals with 349 PCR-detected P. vivax infections within the prior 9 months, using a random forest 350 classification algorithm with antibody responses to a modified set of 8 P. vivax 351 antigens (green, "new") compared to the original 8 (red, "legacy"). In panel A) 352 RBP2b₁₉₈₆₋₂₆₅₃, MSP7L, MSP7F, TRAP, DBPII Sal1, hypothetical (PVX_097715), 353 s16 and EBP, and B) RBP2b₁₆₁₋₁₄₅₄, MSP7L, MSP7F, TRAP, DBPII Sal1, 354 hypothetical (PVX_097715), s16 and EBP. Both panels A and B also include 355 classification using either of the RBP2b₁₉₈₆₋₂₆₅₃ (purple) or RBP2b₁₆₁₋₁₄₅₄ (blue) 356 responses alone.

- 357
- 358

Table 4: Output from *P. vivax* classifier using IgG antibody responses from two adjusted panels of 8 *P. vivax* serological exposure markers with low levels of *P. knowlesi*-cross-reactivity. A classification of previous exposure was taken when predicted probability was greater than a cut off corresponding to the respective

It is made available under a CC-BY-NC-ND 4.0 International license .

363 sensitivity and specificity targets of 72.4% and 70.8% (RBP2b₁₉₈₆₋₂₆₅₃) or 78.7% and

364	76.9%	$(RBP2b_{161-1454})$).	The results	from	Table	2 are	incl	luded	for	comparison	•
											1	

Samples	Total N	Classified	Classified	Classified
		Positive	Positive	Positive
		Legacy 8, number	New 8, with	New 8, with
		(%)	RBP2b ₁₉₈₆₋₂₆₅₃ ,	RBP2b ₁₆₁₋₁₄₅₄ ,
			number (%)	number (%)
ACTKNOW				
Day 0	98	47 (48.0%)	26 (26.5%)	36 (36.7%)
Day 7	99	81 (81.8%)	69 (69.7%)	67 (67.7%)
Day 28	99	68 (68.7%)	43 (43.4%)	49 (49.5%)
PACKNOW				
Day 0	41	21 (51.2%)	12 (29.3%)	12 (29.3%)
Day 7	35	27 (77.1%)	28 (80.0%)	25 (71.4%)
Day 14	15	11 (73.3%)	10 (66.7%)	8 (53.3%)
Day 28	33	20 (60.6%)	19 (57.8%)	14 (42.4%)
Day 365	42	7 (16.7%)	3 (7.1%)	4 (9.5%)

365

366 Association of peak antibody levels with age and *P. knowlesi* parasitaemia

367 Antibody levels are commonly associated with age (i.e. increasing antibodies with 368 increasing age, due to both being a proxy for exposure and age itself), and sometimes 369 with the antigenic input as measured by blood-stage parasitaemia. We further 370 explored whether the cross-reactive antibodies identified at day 7 were associated 371 with either age or *P. knowlesi* parasitaemia (as recorded at enrolment) through 372 regression analyses. This analysis was performed using peak antibody levels at day 7 373 from both the ACTKNOW and PACKNOW cohorts (n=134). There was a weak 374 positive association with age (range 3-78 years) for 11/21 P. vivax antigens (Table 5). In prior studies of *P. knowlesi* malaria age is associated with parasitaemia^{34,35}, thus we 375 376 also adjusted the age analyses for parasitaemia and the findings remained the same 377 (Table 5). Parasitaemia ranged from 56-185,553 parasites/ μ L, and there was no 378 association between *P. knowlesi* parasitaemia and peak antibody levels at day 7 for 379 19/21 P. vivax antigens (Table S2). For DBPII AH there was a negative association

It is made available under a CC-BY-NC-ND 4.0 International license .

between parasitaemia and antibody levels, whereas for MSP7F there was a positive association between parasitaemia and antibody levels. There were also higher antibody levels in females compared to males for four proteins (MSP5, MSP3b, MSP3a, DBPII AH) (Table S2); three of these also had a significant positive association with age which remained after adjustment for sex. No pattern was observed between these associations with the ranking of antigens by cross-reactivity (Table 5).

Table 5: Associations between peak IgG anti-*P. vivax* antibody levels at day 7 in the both *P. knowlesi* cohorts combined with age. Sample

size = 134. Regression analyses were performed univariably and adjusted with parasitaemia. Antigens are ordered by the fold change in the peak

antibody level at day 7 in the ACTKNOW cohort compared to the seropositivity cut-off based on the negative control samples (=Fold Δ IgG). CI

391 = confidence interval.

		Age (unadjusted)		Age (adjusted)	
Protein	Fold Δ IgG	Coefficient (95% CI)	p value	Coefficient (95% CI)	p value
MSP1-19	43.98	0.012 (0.0052-0.02)	0.001	0.012 (0.0052-0.020)	0.001
MSP8	17.07	0.005 (-0.0012-0.011)	0.11	0.005 (-0.0012-0.011)	0.111
Pv-fam-a (PVX_096995)	13.39	0.0047 (-0.00062-0.01)	0.083	0.0047 (-0.00064-0.01)	0.084
RAMA	10.86	0.0046 (-0.0021-0.011)	0.175	0.0046 (-0.0021-0.011)	0.175
PTEX150	6.08	0.013 (0.0053-0.020)	0.001	0.013 (0.0053-0.02)	0.001
MSP5	4.70	0.021 (0.013-0.029)	< 0.0001	0.021 (0.013-0.029)	< 0.0001
RIPR	3.66	0.014 (0.0073-0.021)	< 0.0001	0.014 (0.0073-0.0211)	< 0.0001
RBP2b ₁₆₁₋₁₄₅₄	3.00	0.0077 (0.0012-0.014)	0.02	0.0077 (0.0011-0.014)	0.021
Pv-fam-a (PVX_112670)	2.76	-0.0048 (-0.01-0.0036)	0.068	-0.0048 (-0.01-0.00038)	0.069
RBP2a	2.45	0.012 (0.0071-0.018)	< 0.0001	0.012 (0.007-0.018)	< 0.0001
MSP3b	1.93	0.0064 (0.0014-0.011)	0.013	0.0064 (0.0013-0.012)	0.014
MSP3a	1.92	0.015 (0.0088-0.021)	< 0.0001	0.015 (0.0088-0.021)	< 0.0001
EBP	1.33	0.012 (0.0072-0.016)	< 0.0001	0.012 (0.0072-0.016)	< 0.0001
DBPII AH	1.31	0.0044 (-0.00086-			
		0.0097)	0.1	0.0044 (-0.0008-0.0096)	0.099
S16	1.18	0.0061 (0.00020-0.012)	0.043	0.0061 (0.00018-0.012)	0.044
Hypothetical	1.16	0.0038 (-0.0028-0.010)	0.258	0.0038 (-0.0028-0.01)	0.26
DBPII Sal1	1.02	0.0051 (-0.001-0.011)	0.102	0.0051 (-0.001-0.011)	0.102
TRAP	0.90	0.007 (0.0014-0.013)	0.015	0.007 (0.014-0.013)	0.015
MSP7L	0.78			0.0057 (-0.00013-	
		0.0057 (-0.00012-0.012)	0.055	0.0115)	0.055

MSP7F	0.78	0.0066 (-0.0029-0.013)	0.06	0.0066 (-0.0025-0.013)	0.059
RBP2b ₁₉₈₆₋₂₆₅₃	0.44	0.0042 (-0.0063-0.012)	0.266	0.0042 (-0.0033-0.118)	0.272

It is made available under a CC-BY-NC-ND 4.0 International license .

392 Discussion

393 P. vivax serological markers, that reflect recent exposure to blood-stage P. vivax 394 parasites and can indirectly identify hypnozoite carriers, could play an important role 395 in accelerating malaria elimination programs. In this study, we aimed to identify 396 whether cross-reactive antibodies against our *P. vivax* serological markers were 397 present in patients with recent P. knowlesi infections. Using serial plasma samples 398 from two cohorts of patients with P. knowlesi malaria, we found that cross-reactive 399 antibodies are induced against some of the *P. vivax* proteins assessed. A statistically 400 significant association was seen with the level of sequence identity between the P. 401 vivax and P. knowlesi orthologs. The peak cross-reactive antibody response was at 402 day 7 following infection, which is the same timing as the peak *P. knowlesi*-antibody response reported previously using a similar sample set from Sabah, Malaysia²⁴. This 403 404 is also in line with the timing of peak IgG antibody responses reported for other 405 species such as P. falciparum and P. vivax (within the first two weeks post-406 treatment)³⁶⁻³⁸. Antibodies against the *P. vivax* proteins had reduced in magnitude by 407 day 28 post-infection, and the median IgG levels were below the seropositivity cut-off 408 for all but one *P. vivax* protein (MSP1-19) at 1-year post-*P. knowlesi* infection.

409

410 The two cohorts of *P. knowlesi* clinical case samples used here were obtained during 411 different time periods, 2012-2014 and 2016-2018. The incidence of *P. vivax* 412 infections in Sabah, Malaysia in 2012-2014 was modest and transmission had 413 declined even further by 2016-2018³³. Therefore, the risk that the *P. knowlesi*-infected 414 patients had recent past exposure to *P. vivax* was low in both cohorts (notably, 14 415 patients were retrospectively excluded from the ACTKNOW study due to *P. vivax* 416 infections detected by PCR whilst only 1 was excluded from the PACKNOW study,

It is made available under a CC-BY-NC-ND 4.0 International license .

417 see Methods). The number of *P. vivax* proteins with antibody levels above the sero-418 positive cut-off at the peak of the response was higher in the ACTKNOW cohort in 419 2012-2014 at 80.95% (17/21) compared to 52.38% (11/21) in the PACKNOW cohort 420 in 2016-2018 (this difference was not statistically significant). There was also a 421 significantly higher magnitude of the IgG response in the ACTKNOW cohort 422 compared to the PACKNOW cohort for 9/21 P. vivax proteins at day 7. There was no 423 significant difference in the age between the two cohorts nor the parasitaemia at 424 enrolment (Table 2). Overall, there were still anti-P. vivax antibody responses present 425 in the later PACKNOW cohort and thus our interpretation of these responses as cross-426 reactive is by far the most likely explanation given the evidence (rather than recent 427 past exposure to *P. vivax* infections). Furthermore, the *P. vivax* protein RBP2b is the 428 top serological exposure marker and highly accurate at predicting recent P. vivax 429 infections even when used alone⁹. The lack of antibody responses detected against 430 RBP2b in the *P. knowlesi*-clinical cohorts suggests it is unlikely these patients also 431 had recent *P. vivax* infections.

432

433 Our findings are in line with, but extend upon, past research. An extensive study of P. 434 *vivax –P. knowlesi* antibody cross-reactivity to 19 blood-stage proteins was recently 435 published²³, which included four of the proteins we assessed in the current study 436 (MSP1, MSP8, DBP, RAMA). The authors generated rabbit antibodies against the 19 437 P. vivax proteins and found they recognised P. knowlesi blood-stage parasites through 438 immunofluorescence assays, and were able to inhibit invasion of P. knowlesi into 439 erythrocytes in vitro²³. Naturally acquired antibodies from individuals living in 440 endemic areas were also analysed, with evidence of cross-reactive antibodies from 441 either of P. vivax or P. knowlesi patients against P. vivax or P. knowlesi recombinant

It is made available under a CC-BY-NC-ND 4.0 International license .

442 proteins (building upon the authors' prior work on one *P. vivax* protein, apical 443 asparagine rich protein³⁹). Of relevance to our study, they found significant levels of 444 reactivity in *P. knowlesi* patient sera against *P. vivax* MSP8²³, which is supported by 445 our current data. The 19 P. vivax proteins assessed by Muh and colleagues had high levels of sequence identity with their P. knowlesi orthologs $(>58.2\%)^{23}$, with the 446 447 exception of two RBP proteins (1a and 1b, 22.3 and 26.9%, respectively), and this 448 could explain the universal cross-reactivity they identified. In contrast, our panel of P. 449 vivax proteins had a large spread of sequence identity with their P. knowlesi 450 orthologs, with 9 proteins having less than 50% sequence identity, which enabled us 451 to demonstrate the positive relationship between sequence identity and antibody 452 cross-reactivity. A lower level of sequence identity comes with a decrease in the 453 likelihood of continuous linear epitopes, which is in support of our finding. Further 454 work would need to be undertaken to determine how lower sequence identity affects 455 discontinuous conformational epitopes. Overall, we found the presence and/or level of 456 cross-reactivity is antigen-specific. Our work further extends upon existing findings 457 by demonstrating that cross-reactive antibody responses in *P. knowlesi* patients 458 against *P. vivax* proteins are short-lived.

459

The most cross-reactive protein in our panel was MSP1-19 (>40-fold increase at day 7 compared to sero-positivity cut-off). This magnitude of response is equivalent to that reached against a *P. knowlesi*-specific protein (*Pk*SERA antigen 3) in a subset of these same *P. knowlesi* patient samples (50-fold at day 7 compared to day 0)²⁴. Previous assessment of antibody responses against MSP1-19 in *P. falciparum*, *P. vivax*, *P. malariae* and *P. ovale* (but notably did not include assessment of *P. knowlesi*) indicated a highly species-specific response¹⁶. However, high-levels of

It is made available under a CC-BY-NC-ND 4.0 International license .

467 cross-reactivity for MSP1-19 between P. vivax and P. knowlesi (>81% sequence 468 identity between the Sal1 and H strains, respectively) have been reported in other studies in-line with our work^{23,24}. *P. vivax* MSP1-19 was a vaccine candidate⁴⁰, 469 though has not progressed to clinical trials⁴¹. There remains interest in this 470 candidate^{42,43}, and the high levels of cross-reactivity in our study with *P. knowlesi* 471 suggest that potential cross-species immunity could be possible¹⁵. Recent work has 472 473 used *P. knowlesi* as a model for screening inhibitory activity of *P. vivax* antibodies⁴⁴. 474 Polyclonal antibodies against the *P. vivax* proteins DBP, two 6-cysteine proteins 475 (Pv12, Pv14) and the GPI-anchored micronemal antigen (GAMA) were able to inhibit 476 invasion of wild-type P. knowlesi, demonstrating that cross-species functional 477 immunity is possible (at least *in vitro*). No inhibition was evident against wild-type P. 478 knowlesi when using antibodies against P. vivax MSP3a and MSP7L, which is 479 consistent with our findings of minimal cross-reactivity in P. knowlesi patients for 480 these proteins. In addition to MSP1-19, we observed high levels of potential cross-481 reactive antibody responses against the P. vivax proteins MSP8, Pv-fam-a 482 (PVX 096995) and RAMA. These antigens could thus be considered for assessment of growth inhibitory activity in the *P. knowlesi* model⁴⁴ and considered as potential 483 484 targets for cross-species protection. This is an important consideration given the currently limited landscape of vaccine development specifically for *P. knowlesi*⁴⁵. In 485 486 some previously co-endemic areas of South East Asia, the rise in incidence of 487 symptomatic P. knowlesi malaria has followed the decline in P. vivax malaria, 488 supporting the idea for development of a *P. vivax* vaccine that provides cross-reactive immunity against P. knowlesi⁴⁵. To-date there has been limited assessment of these 489 490 three P. vivax proteins as vaccine candidates. Unfortunately, a number of the most promising *P. vivax* vaccine candidates (including RBP2b, EBP, MSP3a⁴⁶) have low 491

It is made available under a CC-BY-NC-ND 4.0 International license .

492 sequence identify with their *P. knowlesi* orthologs and limited evidence of cross-493 reactivity in our study. Whilst not an objective of our current study, we did identify a 494 number of interesting associations between infection related variables and antibodies 495 against *P. vivax* DBPII, including shorter fever duration and lower parasitemia in *P.* 496 *knowlesi* patients with higher antibodies. This suggests some effect of pre-existing 497 immunity leading to a better ability to control the infection, thus warrants further 498 attention.

499

500 All four of the most highly cross-reactive proteins are within our top 8 panel of P. 501 vivax serological exposure markers⁹. However, levels of antibodies against our top 502 serological marker, RBP2b (N and C terminal constructs), were low. When we 503 applied our previously trained classification algorithm to the current P. knowlesi 504 clinical data sets, 77-82% of *P. knowlesi* patients at the peak antibody time-point (Day 505 7) in each cohort were classified as recently exposed to *P. vivax* blood-stage parasites 506 in the past 9-months. This reduced to 61-69% at Day 28 and 17% at Day 365. As 507 mentioned, at the time of the PACKNOW cohort (2016-2018) local P. vivax 508 transmission in Sabah, Malaysia had approached elimination and nearly all malaria was from *P. knowlesi*³³. Thus, in this cohort there is less risk that the anti-*P. vivax* 509 510 antibody responses measured are due to past exposure to P. vivax, and a lower 511 proportion of *P. knowlesi* patients were accordingly classified as recently exposed 512 compared to the earlier ACTKNOW cohort. However, 77% of PACKNOW patients 513 at Day 7 were classified as recently exposed to *P. vivax*, and thus the substantial 514 cross-reactivity identified against four of our top eight proteins is resulting in this 515 (likely) misclassification. It is important to consider this level of misclassification in

It is made available under a CC-BY-NC-ND 4.0 International license .

areas endemic for both *P. vivax* and *P. knowlesi* in the context of how the serological

- 517 exposure markers will be applied.
- 518

Multiple use-cases for *P. vivax* serological markers $exist^{12}$. For an intervention, such 519 520 as seroTAT, even with potential misclassification due to recent exposure to P. 521 knowlesi, the serological markers would still outperform mass drug administration in 522 terms of specificity. For surveillance purposes, such as identifying clusters of 523 infections or levels of residual transmission to better target the limited resources of 524 malaria control programs, it will be important to define whether the recent exposure 525 was due to P. vivax or P. knowlesi. We therefore assessed performance of an adjusted 526 panel of 8 P. vivax serological markers, which were selected due to low-levels of 527 cross-reactivity in the P. knowlesi clinical cases. Suboptimal performance was 528 initially observed, but after substituting one fragment of RBP2b₁₉₈₆₋₂₆₅₃ for the top 529 performing RBP2b₁₆₁₋₁₄₅₄, this new panel of 8 markers were still able to classify 530 recent P. vivax infections with 78.7% sensitivity and 76.9% specificity, whilst 531 reducing the misclassification of recent P. knowlesi infections to 68-71% at the peak 532 day 7 timepoint. By day 28 this was <50% and importantly at one year post P. 533 knowlesi infection, 10%. This provides proof of principle that an adjusted panel of 534 serological markers could be applied for use in co-endemic areas, but further 535 optimisation would be needed to completely reduce the risk of misclassifying recent 536 P. knowlesi infections. This residual cross-reactivity at one year may assume greater 537 importance for sero-surveillance purposes, as the proportion of all Plasmodium 538 infections due to P. knowlesi rises with P. vivax elimination strategies in co-endemic areas⁴⁵. It would be useful to have plasma samples collected between 1-12 months 539 540 post P. knowlesi-infection to better understand the dynamics of the cross-reactive

It is made available under a CC-BY-NC-ND 4.0 International license .

541 antibody response. An alternative approach would be to include a panel of P. 542 knowlesi-specific markers into the P. vivax serological assay, which could be cross-543 referenced to inform on recent P. knowlesi exposure. Recently a panel of recombinant 544 P. knowlesi proteins has been developed for use as serological tools with care being 545 taken in their design to avoid regions of sequence with high levels of identity with other *Plasmodium* species²⁴. Whilst further validation of species-specificity is 546 547 required, at least one protein (P. knowlesi serine repeat antigen 3 antigen 2) was able to identify *P. knowlesi* exposed individuals²⁴. Further work could also assess the use 548 549 of other Ig isotypes or IgG subclasses detected against the P. vivax serological 550 exposure markers, instead of total IgG, as another avenue for reducing 551 misclassification at later time-points post P. knowlesi-exposure given the possible variability in their longevity^{36,47}. It may also be possible to design smaller *P. vivax* 552 553 protein fragments of the top markers that have very low sequence identitiy with their 554 P. knowlesi orthologs.

555

556 Our study provides important evidence of antibody cross-reactivity against *P. vivax* 557 proteins in patients with P. knowlesi infections, that are relatively short-lived, and 558 provides an approach for limiting the potential misclassification of *Plasmodium* 559 species by serology in co-endemic areas. This data will be useful when interpreting P. 560 vivax sero-surveillance results in settings co-endemic for P. knowlesi. It will be 561 important to expand upon our findings to assess potential cross-reactivity with other zoonotic⁴⁸ and non-zoonotic *Plasmodium* species, even though for the latter the levels 562 563 are expected to be lower due to the further divergence in genetic relatedness with 564 other species¹⁴. Further assessment of recently developed *P. knowlesi* markers of exposure²⁴ in *P. vivax* endemic areas is warranted to confirm limited cross-reactivity 565

It is made available under a CC-BY-NC-ND 4.0 International license .

for those specific proteins between the two species. For our findings to be applied, the new panel of 8 *P. vivax* proteins with limited evidence of cross-reactivity with *P. knowlesi* needs to be validated for a) the ability to identify individuals at risk of recurrent *P. vivax* infections and b) the ability to identify *P. vivax* hypnozoite carriers.

571 Materials and Methods

572 Ethical approvals

573 Samples from two clinical trials conducted in Sabah, Malaysia, were used for this study (ACTKNOW³¹ and PACKNOW³²). Ethical approvals for these studies were 574 575 obtained from the Human Research Ethics Committee at the Menzies School of 576 Health Research, Darwin, Australia (approval numbers 2012-1815 and 16-2544) and 577 the Medical Research and Ethics Committee of the Ministry of Health Malaysia, 578 Malaysia (approval numbers NMRR-12-89-11005 and NMRR-16-29088). All 579 patients gave written informed consent or an attending relative gave informed 580 consent. Ethical approval was provided by the Human Research Ethics Committee at 581 the Walter and Eliza Hall Institute of Medical Research for use of the Malaysian and 582 negative control samples in Melbourne (approval number 14/02).

583

584 Study samples

585 Longitudinal plasma samples were collected from patients enrolled in two *P. knowlesi* 586 clinical trials conducted in Sabah, Malaysia, denoted as ACTKNOW and 587 PACKNOW, and four panels of malaria-naïve negative controls.

588

589 The ACTKNOW study recruited patients over 2012-2014, with the aim of comparing 590 artesunate-mefloquine versus chloroquine for the treatment of acute uncomplicated *P*.

It is made available under a CC-BY-NC-ND 4.0 International license .

knowlesi malaria³¹ (clinicaltrials.gov registration number NCT01708876). Patients 591 592 were recruited from three hospitals (Kudat, Kota Marudu, Pitas) and were eligible for 593 inclusion if they had microscopic diagnosis of P. knowlesi monoinfection, were more 594 than 1 year of age, more than 10kg, had a negative *P. falciparum* rapid diagnostic test, 595 and had a fever ($< 37.5^{\circ}$ C) or history of fever in the past 48 hours. Patients who were 596 not confirmed by PCR to have P. knowlesi monoinfection were retrospectively excluded³¹. Of those excluded, 14 were due to *P. vivax* infections detected upon PCR. 597 598 The duration of self-reported history of fever (days) was recorded. Patients were 599 treated as previously described³¹, with approximately half randomised to receive 600 chloroquine and half to receive artemisinin-based combination therapy. Plasma 601 samples were available for the current study from 99 patients at day 0 (time of 602 enrolment), day 7 and day 28. Data is presented from 98 samples at day 0 for 20/21 P. 603 vivax proteins due to one sample failing quality control of the antibody data, and the 604 incorrect sample being repeated by mistake.

605

606 The PACKNOW study recruited patients over 2016-2018, with the aim or comparing 607 regularly dosed paracetamol versus no paracetamol on renal function in P. knowlesi malaria ³² (clinicaltrials.gov registration number NCT03056391). All patients 608 609 received antimalarial drug treatment with artemether-lumefantrine. Patients were 610 recruited from four hospitals (Queen Elizabeth Hospital, Keningau, Ranau, Kota 611 Marudu) and were eligible for inclusion if they had a microscopic diagnosis of P. 612 knowlesi monoinfection, fever ($\geq 38^{\circ}$ C) on admission or during the preceding 48 613 hours, and were more than 5 years of age. Patients were enrolled within 18 hours of commencing antimalarial treatment³². Patients who were not confirmed by PCR to 614 615 have *P. knowlesi* monoinfection were retrospectively excluded, using a validated PCR

medRxiv preprint doi: https://doi.org/10.1101/2021.12.09.21266664; this version posted December 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

assay⁴⁹. In contrast to the ACTKNOW study, this only included 1 excluded due to *P*. *vivax* infection detected by PCR (unpublished data). Plasma samples were available for the current study from 41 patients at day 0 (time of enrolment), 7, 14, 28 and 365 (these exact time-points were not always available, exact days post-enrolment are stated in the results and relevant figure legends).

621

622 For both the ACTKNOW and PACKNOW cohorts, all patients were PCR-negative 623 for P. vivax co-infection at enrolment, however it was unknown whether the P. 624 knowlesi patients had past exposure to P. vivax parasites. P. vivax has been endemic 625 in Sabah, Malaysia, but the number of malaria cases due to P. vivax has substantially 626 declined from 2009 – 2017 (whilst the number of cases due to P. knowlesi has 627 $risen)^{33}$. In line, the number of patients retrospectively excluded from these studies 628 due to P. vivax infection detected by PCR was 14 in ACTKNOW and only 1 in 629 PACKNOW. All patient data variables are provided in additional file 1.

630

We utilised four panels of malaria-naïve negative control plasma samples as previously described⁹. Briefly, this included 102 individuals from the Volunteer Blood Donor Registry in Melbourne, Australia; 100 individuals from the Australian Red Cross, Melbourne, Australia; 72 individuals from the Thai Red Cross, Bangkok, Thailand; and 96 individuals from the Rio de Janeiro State Blood Bank, Rio de Janeiro, Brazil.

637

638 *P. vivax* proteins

639 21 *P. vivax* proteins were selected for assessment of antibody responses due to their640 ability to classify individuals as recently exposed to *P. vivax* parasites within the prior

medRxiv preprint doi: https://doi.org/10.1101/2021.12.09.21266664; this version posted December 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

9-months, as previously described⁹. These included eight *P. vivax* proteins that,
together, can classify recent *P. vivax* infections with 80% sensitivity and specificity.
Details on the 21 *P. vivax* proteins, including the sequence construct and expression
system, are provided in Table S1. In this manuscript we have referred to proteins by
their annotation, with the PlasmoDB (plasmodb.org/) code in brackets if necessary.
Notations for MSP7 were from Garzón-Ospina 2016⁵⁰ and MSP3 from Kuamsab
2020⁵¹.

648

649 Sequence comparisons between the *P. vivax* proteins with their *P. knowlesi* orthologs 650 was performed by identifying the orthologs in PlasmoDB or through NCBI BlastP. 651 Only H strain and A1H1 line orthologs were selected using PlasmoDB whereas NCBI 652 BlastP included all P. knowlesi strains. Sequence identity and similarity percentages 653 were obtained using the **EMBOSS** Needle protein alignment tool (https://www.ebi.ac.uk/Tools/psa/emboss_needle/)⁵² 654 or NCBI Blast 655 (https://blast.ncbi.nlm.nih.gov/Blast.cgi) directly. PlasmoDB comparisons were made 656 between full-length protein sequences whereas NCBI Blast used the protein 657 sequences of expression constructs as the query sequence.

658

659 Total IgG antibody assay

We used a multiplexed assay based on Luminex xMAP technology to measure total IgG antibody responses to the 21 *P. vivax* proteins. This assay was run on a MAGPIX instrument, as previously described⁵³. Briefly, the 21 *P. vivax* proteins were coupled to individual sets of internally labelled magnetic COOH beads at previously determined optimal concentrations (see Table S1) following standard methods⁵³. Antigen-specific total IgG was detected in plasma samples by incubating 500 coupled

It is made available under a CC-BY-NC-ND 4.0 International license .

666	beads of each antigen per well with plasma diluted at 1:100 in PBT (1x PBS with 1%
667	BSA and 0.05% Tween-20), followed after incubation by the addition of 0.5mg/ml
668	PE-conjugated Donkey F(ab)2 anti-human IgG (JIR 709-116-098). On each plate, a
669	two-fold serial dilution from 1/50 to 1/25,600 of a positive control hyperimmune
670	plasma pool (generated from adults from PNG, a non-knowlesi-endemic region) was
671	included. At least 15 beads per region were then acquired and read on a MAGPIX
672	instrument as per the manufacturer's instructions, with results expressed as the mean
673	fluorescent intensity (MFI). All serology data is available in additional files 2 and 3.

674

675 Existing datasets of total IgG antibodies against the same P. vivax proteins in three observational cohort studies (in P. vivax-endemic areas) were also used⁹. These data 676 were generated as previously described⁹ using a similar multiplexed assay, but with 677 678 non-magnetic beads and run on a Luminex-200 instrument. Briefly, yearlong cohort 679 studies were conducted in Thailand (Kanchanaburi and Ratchaburi provinces), and in 680 non-knowlesi endemic Brazil (Manaus) and the Solomon Islands (Ngella) across 681 2013-2014. Each site enrolled between 928-1274 individuals with blood samples 682 taken every month for qPCR detection of P. vivax infections and plasma stored for antibody measurements. This enabled total IgG antibody responses measured at the 683 684 final visit of the yearlong cohorts to be related to the time since prior P. vivax 685 infection. These existing datasets are available here: https://github.com/MWhite-686 InstitutPasteur/Pvivax_sero_dx.

687

688 Statistical analysis

689 The raw MFI results were converted to relative antibody units (RAU) using protein-690 specific standard curve data, as previously described⁵³. A five-parameter logistic

It is made available under a CC-BY-NC-ND 4.0 International license .

691 function was used to obtain an equivalent dilution value (expressed as the RAU) 692 compared to the PNG control plasma, with extrapolation one step beyond the lowest dilution resulting in a range of values from 1.95x10⁻⁵ to 0.02 RAU. The standard 693 694 curve conversion was performed in R version 4.1.1. Spearman's r correlations were 695 performed to correlate sequence identity with relative cross-reactivity levels. 696 Spearman r values <0.3 were considered weak, 0.3–0.7 moderate, and >0.7 strong 697 correlations. Mann-Whitney U tests were used to compare antibody levels between 698 various patient variables, or to compare antibody levels across cohorts. Fisher's exact 699 tests were used to compare categorical variables or outcomes. Correlations, Mann-700 Whitney U tests and Fisher's exact tests were performed in Prism version 9. Linear 701 regression analyses to assess associations between peak antibody levels with age, sex 702 and parasitaemia were performed in Stata version 12. Antibody levels were first log10 703 transformed to better for a normal distribution.

704

705 Classification of recent *P. vivax* infections within the prior 9-months was performed 706 using a Random Forest classification algorithm. The algorithm used antibody data 707 against the top eight P. vivax serological exposure markers that we had previously 708 identified⁹, and was trained with 4 existing datasets from our previous work (Thailand n=826, Brazil n=925, Solomon Islands n=754 and negative controls $n=274)^9$. The top 709 710 eight proteins were: MSP1-19, Pv-fam-a (PVX 096995), Pv-fam-a (PVX 112670), 711 RAMA, MSP8, MSP3a, RBP2b₁₆₁₋₁₄₅₄, and EBP. A diagnostic target of 79% 712 specificity and 79% sensitivity was selected.

713

Two modified sets of eight proteins were also tested in the classification algorithm,
based on low cross-reactivity in the *P. knowlesi* clinical patient samples. A random

It is made available under a CC-BY-NC-ND 4.0 International license .

716 forest classification algorithm was trained, using existing antibody data generated 717 against the modified sets of eight proteins in our Thai, Brazilian and Solomon Islands 718 studies⁹. The classification algorithm was cross-validated using 1000 randomly 719 sampled, disjoint training and testing subsets, and the data presented in a receiver 720 operating characteristic curve, with credible intervals corresponding to percentiles 721 calculated among replicates. At every iteration, 2/3 of each cohort was used for 722 training and 1/3 for testing. This newly modified and trained random forest algorithm 723 was subsequently used to classify the samples from the *P. knowlesi* clinical cohorts as 724 recently exposed to *P. vivax* blood-stage parasites in the prior 9-months, or not, with 725 the optimal balanced diagnostic target that was achievable as per Youden's J.

726

727 Acknowledgments

728 We acknowledge the efforts of the original study teams for collecting the P. knowlesi 729 clinical samples. We thank Shazia Ruybal for support generating an automated 730 quality control platform through R, based on prior work by Connie Li-Wai-Suen, 731 which was also used for the standard curve conversion. We thank Sarah Miller for 732 assistance with ethical approvals. We would like to thank the Director-General, 733 Ministry of Health, Malaysia, for permission to publish this manuscript. We also 734 acknowledge the Victorian State Government Operational Infrastructure Support and 735 Australian Government NHMRC IRIISS.

736

737 Funding

738 WEHI Innovation Fund (RL, TT, IM)

It is made available under a CC-BY-NC-ND 4.0 International license .

- 739 Clinical Trials Funding: Malaysian Ministry of Health (grant number BP00500420),
- the Asia Pacific Malaria Elimination Network (108-07), and the Australian National
- Health and Medical Research Council (NHMRC; 1037304, 1045156, 115680)
- 742 NHMRC Fellowships to NMA #1135820, MJG #1138860 and RL #1173210
- 743 NHMRC grants #1092789, #1134989, #1132975 and #1043345 (IM)
- 744

745 Author contributions

- 746 Conceptualization: RL, MG, NA, IM
- 747 Methodology clinical trials & control samples: RL, MG, KP, JS, BB, DC, TW, NA,
- 748 IM
- 749 Methodology protein expression: ET, TT, MH, CEC, JH, WHT
- 750 Methodology antibody assays & analytics: RL, KS, RM, NN, TO, MW
- 751 Investigation laboratory: RL, KS, SH, RM
- 752 Investigation analytics: RL, KS, TO, MW
- 753 Visualization: RL, KS, TO, MW
- 754 Supervision: NA, IM
- 755 Writing original draft: RL
- 756 Writing reviewing & editing: RL, MG, KS, SH, KP, NN, TO, RM, ET, TT, MH,
- 757 CEC, DC, KT, CD, JH, WHT, JS, MW, BB, TW, NA, TM
- 758

759 **Competing interests**

- 760 RL, MW, TT and IM are inventors on filed patent PCT/US17/67926 on a system,
- 761 method, apparatus and diagnostic test for *P. vivax*. MH was an employee of the
- 762 company CellFree Sciences Co., Ltd. All other authors declare they have no
- competing interests.

It is made available under a CC-BY-NC-ND 4.0 International license .

764

765 Data and materials availability

- All data are available in the main text or the supplementary materials. Additional File
- 1 contains patient variables, Additional File 2 contains IgG antibody data from the *P*.
- 768 knowlesi cohorts and Additional File 3 IgG antibody data from the malaria-naïve
- 769 controls.
- 770

771 References

- Price, R.N., Commons, R.J., Battle, K.E., Thriemer, K., and Mendis, K. (2020).
 Plasmodium vivax in the Era of the Shrinking P. falciparum Map. Trends
 Parasitol 36, 560-570. 10.1016/j.pt.2020.03.009.
- 775 2. Kho, S., Qotrunnada, L., Leonardo, L., Andries, B., Wardani, P.A.I., Fricot, A., 776 Henry, B., Hardy, D., Margyaningsih, N.I., Apriyanti, D., et al. (2021). 777 Hidden Biomass of Intact Malaria Parasites in the Human Spleen. The 778 New England journal of medicine 384, 2067-2069. 779 10.1056/NEJMc2023884.
- Kho, S., Qotrunnada, L., Leonardo, L., Andries, B., Wardani, P.A.I., Fricot, A., Henry, B., Hardy, D., Margyaningsih, N.I., Apriyanti, D., et al. (2021).
 Evaluation of splenic accumulation and colocalization of immature reticulocytes and Plasmodium vivax in asymptomatic malaria: A prospective human splenectomy study. PLoS Med 18, e1003632.
 10.1371/journal.pmed.1003632.
- Moreira, C.M., Abo-Shehada, M., Price, R.N., and Drakeley, C.J. (2015). A
 systematic review of sub-microscopic Plasmodium vivax infection. Malar J
 14, 360. 10.1186/s12936-015-0884-z.
- 5. Kiattibutr, K., Roobsoong, W., Sriwichai, P., Saeseu, T., Rachaphaew, N.,
 Suansomjit, C., Buates, S., Obadia, T., Mueller, I., Cui, L., et al. (2017).
 Infectivity of symptomatic and asymptomatic Plasmodium vivax
 infections to a Southeast Asian vector, Anopheles dirus. Int J Parasitol 47,
 163-170. 10.1016/j.ijpara.2016.10.006.
- Robinson, L.J., Wampfler, R., Betuela, I., Karl, S., White, M.T., Li Wai Suen,
 C.S., Hofmann, N.E., Kinboro, B., Waltmann, A., Brewster, J., et al. (2015).
 Strategies for understanding and reducing the Plasmodium vivax and
 Plasmodium ovale hypnozoite reservoir in Papua New Guinean children:
 a randomised placebo-controlled trial and mathematical model. PLoS Med
 e1001891. 10.1371/journal.pmed.1001891.
- Commons, R.J., Simpson, J.A., Watson, J., White, N.J., and Price, R.N. (2020).
 Estimating the Proportion of Plasmodium vivax Recurrences Caused by
 Relapse: A Systematic Review and Meta-Analysis. The American journal of
 tropical medicine and hygiene *103*, 1094-1099. 10.4269/ajtmh.20-0186.
- 804 8. Adekunle, A., Pinkevych, M., McGready, R., Luxemburger, C., White, L., 805 Nosten, F., Cromer, D., and Davenport, M. (2015). Modeling the dynamics

806		of Plasmodium vivax infection and hypnozoite reactivation in vivo. PLoS
807		Negl Trop Dis 9, e0003595.
808	9.	Longley, R.J., White, M.T., Takashima, E., Brewster, J., Morita, M., Harbers,
809		M., Obadia, T., Robinson, L.J., Matsuura, F., Liu, Z.S.J., et al. (2020).
810		Development and validation of serological markers for detecting recent
811		Plasmodium vivax infection. Nature medicine 26, 741-749.
812		10.1038/s41591-020-0841-4
813	10.	White, N.J. (2011). Determinants of relapse periodicity in Plasmodium
814		vivax malaria. Malar J <i>10</i> , 297. 10.1186/1475-2875-10-297.
815	11.	Chotirat, S., Nekkab, N., Kumpitak, C., Hietanen, J., White, M.T., Kiattibutr,
816		K., Sa-angchai, P., Brewster, J., Schoffer, K., Takashima, E., et al. (2021).
817		Application of 23 Novel Serological Markers for Identifying Recent
818		Exposure to Plasmodium vivax Parasites in an Endemic Population of
819		Western Thailand. Frontiers in Microbiology 12.
820		10.3389/fmicb.2021.643501.
821	12.	Greenhouse, B., Daily, J., Guinovart, C., Goncalves, B., Beeson, J., Bell, D.,
822		Chang, M.A., Cohen, J.M., Ding, X., Domingo, G., et al. (2019). Priority use
823		cases for antibody-detecting assays of recent malaria exposure as tools to
824		achieve and sustain malaria elimination. Gates Open Res 3, 131.
825		10.12688/gatesopenres.12897.1.
826	13.	WHO (2020). World Malaria Report. World Health Organisation.
827	14.	Loy, D.E., Liu, W., Li, Y., Learn, G.H., Plenderleith, L.J., Sundararaman, S.A.,
828		Sharp, P.M., and Hahn, B.H. (2017). Out of Africa: origins and evolution of
829		the human malaria parasites Plasmodium falciparum and Plasmodium
830		vivax. Int J Parasitol 47, 87-97. 10.1016/j.ijpara.2016.05.008.
831	15.	Mitran, C.J., and Yanow, S.K. (2020). The Case for Exploiting Cross-Species
832		Epitopes in Malaria Vaccine Design. Front Immunol 11, 335.
833		10.3389/fimmu.2020.00335.
834	16.	Priest, J.W., Plucinski, M.M., Huber, C.S., Rogier, E., Mao, B., Gregory, C.J.,
835		Candrinho, B., Colborn, J., and Barnwell, J.W. (2018). Specificity of the IgG
836		antibody response to Plasmodium falciparum, Plasmodium vivax,
837		Plasmodium malariae, and Plasmodium ovale MSP1(19) subunit proteins
838		in multiplexed serologic assays. Malar J 17, 417. 10.1186/s12936-018-
839		2566-0
840	17.	Woodberry, T., Minigo, G., Piera, K.A., Hanley, J.C., de Silva, H.D., Salwati, E.,
841		Kenangalem, E., Tjitra, E., Coppel, R.L., Price, R.N., et al. (2008). Antibodies
842		to Plasmodium falciparum and Plasmodium vivax merozoite surface
843		protein 5 in Indonesia: species-specific and cross-reactive responses. J
844		Infect Dis <i>198</i> , 134-142. 10.1086/588711.
845	18.	Diggs, C.L., and Sadun, E.H. (1965). SEROLOGICAL CROSS REACTIVITY
846		BETWEEN PLASMODIUM VIVAX AND PLASMODIUM FALCIPARUM AS
847		DETERMINED BY A MODIFIED FLUORESCENT ANTIBODY TEST. Exp
848		Parasitol <i>16</i> , 217-223. 10.1016/0014-4894(65)90046-9.
849	19.	Lacerda, M.V.G., and Bassat, Q. (2019). Primaquine for all: is it time to
850		simplify malaria treatment in co-endemic areas? Lancet Infect Dis 19, 10-
851		12. 10.1016/s1473-3099(18)30612-1.
852	20.	Looareesuwan, S., White, N.J., Chittamas, S., Bunnag, D., and Harinasuta, T.
853		(1987). High rate of Plasmodium vivax relapse following treatment of
854		falciparum malaria in Thailand. Lancet 2, 1052-1055.

- Douglas, N.M., Nosten, F., Ashley, E.A., Phaiphun, L., van Vugt, M.,
 Singhasivanon, P., White, N.J., and Price, R.N. (2011). Plasmodium vivax
 recurrence following falciparum and mixed species malaria: risk factors
 and effect of antimalarial kinetics. Clin Infect Dis 52, 612-620.
 10.1093/cid/ciq249.
- Hossain, M.S., Commons, R.J., Douglas, N.M., Thriemer, K., Alemayehu, B.H., 860 22. 861 Amaratunga, C., Anvikar, A.R., Ashley, E.A., Asih, P.B.S., Carrara, V.I., et al. 862 (2020). The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide 863 864 Antimalarial Resistance Network. PLoS Med 17, e1003393. 865 10.1371/journal.pmed.1003393.
- 23. 866 Muh, F., Kim, N., Nyunt, M.H., Firdaus, E.R., Han, J.H., Hogue, M.R., Lee, S.K., 867 Park, J.H., Moon, R.W., Lau, Y.L., et al. (2020). Cross-species reactivity of 868 antibodies against Plasmodium vivax blood-stage antigens to Plasmodium 869 knowlesi. PLoS Negl Trop Dis 14. e0008323. 870 10.1371/journal.pntd.0008323.
- 871 24. Herman, L.S., Fornace, K., Phelan, J., Grigg, M.J., Anstey, N.M., William, T.,
 872 Moon, R.W., Blackman, M.J., Drakeley, C.J., and Tetteh, K.K.A. (2018).
 873 Identification and validation of a novel panel of Plasmodium knowlesi
 874 biomarkers of serological exposure. PLoS Negl Trop Dis *12*, e0006457.
 875 10.1371/journal.pntd.0006457.
- Fornace, K.M., Herman, L.S., Abidin, T.R., Chua, T.H., Daim, S., Lorenzo, P.J.,
 Grignard, L., Nuin, N.A., Ying, L.T., Grigg, M.J., et al. (2018). Exposure and
 infection to Plasmodium knowlesi in case study communities in Northern
 Sabah, Malaysia and Palawan, The Philippines. PLoS Negl Trop Dis *12*,
 e0006432. 10.1371/journal.pntd.0006432.
- 26. Cuenca, P.R., Key, S., Jumail, A., Surendra, H., Ferguson, H.M., Drakeley, C.J.,
 and Fornace, K. (2021). Epidemiology of the zoonotic malaria
 Plasmodium knowlesi in changing landscapes. Adv Parasitol *113*, 225286. 10.1016/bs.apar.2021.08.006.
- 885 27. Grigg, M.J., Cox, J., William, T., Jelip, J., Fornace, K.M., Brock, P.M., von
 886 Seidlein, L., Barber, B.E., Anstey, N.M., Yeo, T.W., and Drakeley, C.J. (2017).
 887 Individual-level factors associated with the risk of acquiring human
 888 Plasmodium knowlesi malaria in Malaysia: a case-control study. Lancet
 889 Planet Health 1, e97-e104. 10.1016/s2542-5196(17)30031-1.
- Barber, B.E., Grigg, M.J., William, T., Yeo, T.W., and Anstey, N.M. (2017).
 The Treatment of Plasmodium knowlesi Malaria. Trends Parasitol 33, 242-253. 10.1016/j.pt.2016.09.002.
- Pain, A., Böhme, U., Berry, A.E., Mungall, K., Finn, R.D., Jackson, A.P.,
 Mourier, T., Mistry, J., Pasini, E.M., Aslett, M.A., et al. (2008). The genome
 of the simian and human malaria parasite Plasmodium knowlesi. Nature
 455, 799-803. 10.1038/nature07306.
- 897 30. Benavente, E.D., de Sessions, P.F., Moon, R.W., Grainger, M., Holder, A.A.,
 898 Blackman, M.J., Roper, C., Drakeley, C.J., Pain, A., Sutherland, C.J., et al.
 899 (2018). A reference genome and methylome for the Plasmodium knowlesi
 900 A1-H.1 line. Int J Parasitol 48, 191-196. 10.1016/j.ijpara.2017.09.008.
- 901 31. Grigg, M.J., William, T., Menon, J., Dhanaraj, P., Barber, B.E., Wilkes, C.S.,
 902 von Seidlein, L., Rajahram, G.S., Pasay, C., McCarthy, J.S., et al. (2016).
 903 Artesunate-mefloquine versus chloroquine for treatment of

904		uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW):
905		an open-label, randomised controlled trial. Lancet Infect Dis 16, 180-188.
906		10.1016/s1473-3099(15)00415-6
907	32.	Cooper, D.J., Plewes, K., Grigg, M.J., Rajahram, G.S., Piera, K.A., William, T.,
908		Chatfield, M.D., Yeo, T.W., Dondorp, A.M., Anstey, N.M., and Barber, B.E.
909		(2018). The effect of regularly dosed paracetamol versus no paracetamol
910		on renal function in Plasmodium knowlesi malaria (PACKNOW): study
911		protocol for a randomised controlled trial. Trials 19, 250.
912		10.1186/s13063-018-2600-0.
913	33.	Cooper, D.L. Rajahram, G.S., William, T., Jelin, L. Mohammad, R., Benedict,
914		L. Alaza, D.A. Malacova, E., Yeo, T.W., Grigg, M.L. et al. (2020). Plasmodium
915		knowlesi Malaria in Sabah. Malaysia. 2015-2017: Ongoing Increase in
916		Incidence Despite Near-elimination of the Human-only Plasmodium
917		Species Clin Infect Dis 70 361-367 10 1093/cid/ciz237
918	34	Barber BE Grigg MI William T Piera KA Boyle MI Yeo TW and
919	011	Anstev NM (2017) Effects of Aging on Parasite Biomass Inflammation
920		Endothelial Activation Microvascular Dysfunction and Disease Severity in
921		Plasmodium knowlesi and Plasmodium falcinarum Malaria. I Infect Dis
922		215 1908-1917 10 1093/infdis/jix193
923	35	Grigg MI William T Barber BE Rajahram GS Menon I Schimann E
924	00.	Piera K Wilkes CS Patel K Chandna A et al (2018) Age-Related
925		Clinical Spectrum of Plasmodium knowlesi Malaria and Predictors of
926		Severity Clin Infect Dis 67 350-359 10 1093/cid/civ065
927	36	Rogier F Nace D Dimby PR Wakeman B Pohl I Beeson IG
927	50.	Drakeley C Tetteh K and Plucinski M (2021) Framework for
020		Characterizing Longitudinal Antibody Response in Children After
929		Plasmodium falcinarum Infection Front Immunol 12 617051
031		10.3280/fimmu 2021 617051
032	37	Vman V White MT Asghar M Sundling C Sondén K Draner SL
033	57.	Osier EHA and Eärnert A (2019) Antibody responses to merozoite
933		osier, F.H.A., and Fameric, A. (2019). Antibody responses to merozoite
934		longevity in charge of recomposition BMC Mod 17, 22, 10, 1196/c12016
935		010 1255 2
930	20	U17-1253-3. Liu 75 I Sottahongkat I White M Chatinat S Kumpitale C
937	50.	Talvashima E. Harbara M. Thom W. H. Haalar I. Chitnia C.E. at al
930		(2021) Naturally acquired antihody hinstics against Diamodium vivor
939		(2021). Naturally acquired antibody kinetics against Plasmodium vivas
940		Theiland his Driv 2021 2010 2021 464164 10 1101 (2021 10 21 464164
941	20	Inaliand. DioKXIV, 2021.2010.2021.404104. 10.1101/2021.10.21.404104.
942	39.	Mun, F., Anmeu, M.A., Han, J.H., Nyunt, M.H., Lee, S.K., Lau, Y.L., Kaneko, O.,
945		and Han, E.I. (2018). Cross-species analysis of apical asparagine-rich
944		protein of Plasmodium vivax and Plasmodium knowlesi. Scientific reports
945	10	8,5/81,10.1038/841598-018-23/28-1.
946	40.	Rosa, D.S., IWal, L.K., Izelepis, F., Bargieri, D.Y., Medeiros, M.A., Soares, I.S.,
94/		Signey, J., Sette, A., Kalli, J., Mello, L.E., et al. (2006). Immunogenicity of a
948		recombinant protein containing the Plasmodium vivax vaccine candidate
949		MSPI(19) and two numan UD4+ 1-cell epitopes administered to non-
950		numan primates (Callithrix jacchus jacchus). Microbes Infect 8, 2130-
951		2137. 10.1016/j.micint.2006.03.012.

- 95241.De, S.L., Ntumngia, F.B., Nicholas, J., and Adams, J.H. (2021). Progress953towards the development of a P. vivax vaccine. Expert Rev Vaccines 20,95497-112. 10.1080/14760584.2021.1880898.
- 42. Kale, S., Yadav, C.P., Rao, P.N., Shalini, S., Eapen, A., Srivasatava, H.C.,
 Sharma, S.K., Pande, V., Carlton, J.M., Singh, O.P., and Mallick, P.K. (2019).
 Antibody responses within two leading Plasmodium vivax vaccine
 candidate antigens in three geographically diverse malaria-endemic
 regions of India. Malar J 18, 425. 10.1186/s12936-019-3066-6.
- McCaffery, J.N., Fonseca, J.A., Singh, B., Cabrera-Mora, M., Bohannon, C.,
 Jacob, J., Arévalo-Herrera, M., and Moreno, A. (2019). A Multi-Stage
 Plasmodium vivax Malaria Vaccine Candidate Able to Induce Long-Lived
 Antibody Responses Against Blood Stage Parasites and Robust
 Transmission-Blocking Activity. Front Cell Infect Microbiol 9, 135.
 10.3389/fcimb.2019.00135.
- 966 44. Ndegwa, D.N., Kundu, P., Hostetler, J.B., Marin-Menendez, A., Sanderson,
 967 T., Mwikali, K., Verzier, L.H., Coyle, R., Adjalley, S., and Rayner, J.C. (2021).
 968 Using Plasmodium knowlesi as a model for screening Plasmodium vivax
 969 blood-stage malaria vaccine targets reveals new candidates. PLoS Pathog
 970 17, e1008864. 10.1371/journal.ppat.1008864.
- 45. Anstey, N.M., and Grigg, M.J. (2019). Zoonotic Malaria: The Better You
 book, the More You Find. J Infect Dis 219, 679-681. 10.1093/infdis/jiy520.
- 46. Franca, C.T., White, M.T., He, W.Q., Hostetler, J.B., Brewster, J., Frato, G.,
 Malhotra, I., Gruszczyk, J., Huon, C., Lin, E., et al. (2017). Identification of
 highly-protective combinations of Plasmodium vivax recombinant
 proteins for vaccine development. Elife 6. 10.7554/eLife.28673.
- 977 47. Ssewanyana, I., Rek, J., Rodriguez, I., Wu, L., Arinaitwe, E., Nankabirwa, J.I., 978 Beeson, J.G., Mayanja-Kizza, H., Rosenthal, P.J., Dorsey, G., et al. (2021). 979 Impact of a Rapid Decline in Malaria Transmission on Antimalarial IgG 980 and Subclasses Avidity. Frontiers in Immunology 11. 981 10.3389/fimmu.2020.576663.
- 48. Yap, N.J., Hossain, H., Nada-Raja, T., Ngui, R., Muslim, A., Hoh, B.P., Khaw,
 983 L.T., Kadir, K.A., Simon Divis, P.C., Vythilingam, I., et al. (2021). Natural
 984 Human Infections with Plasmodium cynomolgi, P. inui, and 4 other Simian
 985 Malaria Parasites, Malaysia. Emerg Infect Dis 27, 2187-2191.
 986 10.3201/eid2708.204502.
- 987 49. Nuin, N.A., Tan, A.F., Lew, Y.L., Piera, K.A., William, T., Rajahram, G.S., Jelip,
 988 J., Dony, J.F., Mohammad, R., Cooper, D.J., et al. (2020). Comparative
 989 evaluation of two commercial real-time PCR kits (QuantiFast[™] and
 990 abTES[™]) for the detection of Plasmodium knowlesi and other
 991 Plasmodium species in Sabah, Malaysia. Malar J 19, 306. 10.1186/s12936992 020-03379-2.
- 50. Garzón-Ospina, D., Forero-Rodríguez, J., and Patarroyo, M.A. (2016).
 Evidence of functional divergence in MSP7 paralogous proteins: a
 molecular-evolutionary and phylogenetic analysis. BMC Evol Biol 16, 256.
 10.1186/s12862-016-0830-x.
- 51. Kuamsab, N., Putaporntip, C., Pattanawong, U., and Jongwutiwes, S.
 (2020). Insights into the molecular diversity of Plasmodium vivax
 merozoite surface protein-3γ (pvmsp3γ), a polymorphic member in the

1000		msp3 multi-gene family. Scientific reports 10, 10977. 10.1038/s41598-
1001		020-67222-z.
1002	52.	Needleman, S.B., and Wunsch, C.D. (1970). A general method applicable to
1003		the search for similarities in the amino acid sequence of two proteins. J
1004		Mol Biol <i>48,</i> 443-453. 10.1016/0022-2836(70)90057-4.
1005	53.	Mazhari, R., Brewster, J., Fong, R., Bourke, C., Liu, Z.S.J., Takashima, E.,
1006		Tsuboi, T., Tham, W.H., Harbers, M., Chitnis, C., et al. (2020). A comparison
1007		of non-magnetic and magnetic beads for measuring IgG antibodies against
1008		Plasmodium vivax antigens in a multiplexed bead-based assay using
1009		Luminex technology (Bio-Plex 200 or MAGPIX). PLoS One 15, e0238010.
1010		10.1371/journal.pone.0238010.
1011		

Supplementary Information



Figure S1: IgG antibody levels against 21 *P. vivax* proteins in 98 individuals with matched data over time. IgG levels were measured against the 21 *P. vivax* proteins using a multiplexed antibody assay. Samples were obtained and run at the time of *P. knowlesi* infection (day 0), and days 7 and 28 following enrolment (ACTKNOW cohort). Results are expressed as the relative antibody units (RAU). Proteins are ordered by highest level of median IgG at day 7 compared to the seropositivity cut-off. Dashed lines indicate the malaria-naïve negative control samples: lower = average of the negative control samples; upper = seropositivity cut-off (average plus 2x standard deviation).



Figure S2: Correlation between acquisition of IgG antibodies at Day 0 to *P. vivax* DBPII constructs and duration of fever of *P. knowlesi* patients. IgG levels were measured against the 21 *P. vivax* proteins using a multiplexed antibody assay. Samples were obtained and run at the time of *P. knowlesi* infection (day 0), and days 7 and 28 following enrolment (ACTKNOW cohort). Results are expressed as the relative antibody units (RAU). Here, IgG antibody data at day 0 were correlated with the duration of fever (days) reported by the *P. knowlesi* patients. Data are shown for the only two proteins with a statistically significant correlation, DBPII AH and Sal1. Dashed lines indicate the malaria-naïve negative control samples: lower = average of the negative control samples; upper = seropositivity cut-off (average plus 2x standard deviation). The third plot shows the correlation between antibodies between both DBPII constructs. Spearman correlation co-efficients are shown.



Figure S3: IgG antibody levels against 21 *P. vivax* proteins in *P. knowlesi* patients split via clinical trial. IgG levels were measured against the 21 *P. vivax* proteins using a multiplexed antibody assay. Samples were obtained and run at the time of *P. knowlesi* infection (day 0), and days 7 and 28 following enrolment (ACTKNOW and PACKNOW cohorts). Further data timepoints were available for PACKNOW but are not shown. Results are expressed as the relative antibody units (RAU). Proteins are ordered by highest level of median IgG at day 7 compared to the seropositivity cut-off. Dashed lines indicate the malaria-naïve negative control samples: lower = average of the negative control samples; upper = seropositivity cut-off (average plus 2x standard deviation). Data are split via clinical trial; the ACTKNOW cohort (n=99) and the PACKNOW cohort (n=41 at day 0). Statistical difference in antibody levels between clinical trial groups was only assessed at the peak timepoint of day 7, using Mann-Whitney U tests. 9 of 21 *P. vivax* proteins induced significantly higher levels in ACTKNOW vs PACKNOW: RBP2b₁₆₁₋₁₄₅₄ (p=0.0019), MSP3b (p=0.0095), DBPII AH (p=0.0064), RIPR (p=0.013), MSP3a (p=0.0002), MSP5 (p=0.021), RBP2a (p=0.046), DBPII Sal1 (p=0.0049) and EBP (p=0.0007).

Protein	PlasmoDB code/GenBank ID	Full Annotation	Region, amino acids (size)	Expression system	µg protein coupled to 2.5x10 ⁶ beads	
RBP2b ₁₆₁₋₁₄₅₄	PVX_094255	Reticulocyte binding protein 2b (n-terminal fragment)	161-1454 (1294)	E. coli, WEHI	0.6	
MSP1-19	PVX_099980	Merozoite surface protein 1 - 19	1622-1729 (108)	WGCF, CellFree Sciences	4	
RBP2b ₁₉₈₆₋₂₆₅₃	PVX_094255	Reticulocyte binding protein 2b (c-terminal fragment)	1986-2653 (667)	WGCF, CellFree Sciences	8	
EBP	KMZ83376.1	Erythrocyte binding protein	109-432 (324)	E. coli, Institut Pasteur	0.5	
s16	PVX_000930	Sexual stage antigen S16	31-end (110)	WGCF, CellFree Sciences	2	
RIPR	PVX_095055	Rh5 interacting protein	552-1075 (524)	E. coli, WEHI	2	
MSP3a	PVX_097720	Merozoite surface protein 3	25-end (828)	WGCF, CellFree Sciences	2	
Hypothetical	PVX_097715	Hypothetical protein	20-end (431)	WGCF, CellFree Sciences	3	
DBPII AH	AAY34130.1	Duffy binding protein region II (strain AH)	1-237 (237)	E. coli, Institut Pasteur	1.4	
MSP8	PVX_097625	Merozoite surface protein 8	24-463 (440)	WGCF, CellFree Sciences	1.4	
Pv-fam-a	PVX_112670	Pv-fam-a	34-end (302)	WGCF, CellFree Sciences	2.26	
RAMA	PVX_087885	Rhoptry associated membrane antigen	462-730 (269)	WGCF, CellFree Sciences	1.2	
Pv-fam-a	PVX_096995	Pv-fam-a	61-end (420)	WGCF, CellFree Sciences	3	
MSP3b	PVX_097680	Merozoite surface protein 3	21-end (996)	WGCF, CellFree Sciences	0.8	
MSP7L	PVX_082700	Merozoite surface protein 7	23-end (397)	WGCF, CellFree Sciences	1.5	
MSP5	PVX_003770	Merozoite surface protein 5	23-365 (343)	WGCF, CellFree Sciences	0.2	
MSP7F	PVX_082670	Merozoite surface protein 7	24-end (388)	WGCF, CellFree Sciences	1	
TRAP	PVX_082735	Thrombospondin related adhesion protein (also known as SSP2)	26-493 (468)	WGCF, CellFree Sciences	2	
DBPII Sal1	PVX_110810	Duffy binding protein region II (strain Sal1)	193-521 (329)	E. coli, Institut Pasteur	1.5	
PTEX150	PVX_084720	translocon component PTEX150, putative	24-908 (885)	WGCF, CellFree Sciences	1	
RBP2a	PVX_121920	Reticulocyte binding protein 2a	160-1135 (976)	E. coli, WEHI	1.5	

Table S1: Proteins used in this study.

Table S2: Association between peak antibody levels at day 7 with parasitaemia and sex. Sample size = 134. Regression analyses were							
performed univariably. Antigens are ordered by the fold change in the peak antibody level at day 7 compared to the seropositivity cut-off based							
on the negative control samples (=Fold Δ IgG). Fold change data shown is from the ACTKNOW cohort. CI = confidence interval.							

		Parasitaemia		Sex		
Protein	Fold ∆ IgG	Coefficient (95% CI)	p value	Coefficient (95% CI)	p value	
MSP1-19	43.98	-2.22e-6 (-8.69e-6-4.25e-6)	0.498	0.051 (-0.23-0.33)	0.724	
MSP8	17.07	-3.31e-7 (-3.9e-6 - 3.24e-6)	0.855	0.17 (-0.06-0.42)	0.146	
Pv-fam-a (PVX_096995)	13.39	-5.35e-7 (-4.02e-6-2.94e-6)	0.761	0.12 (-0.07-0.32)	0.207	
RAMA	10.86	-1.41e-6 (-4.02e-6-1.2e-6)	0.287	0.23 (-0.015-0.47)	0.065	
PTEX150	6.08	3.64e-7 (-2.59e-6-3.32e-6)	0.808	0.11 (-0.13-0.34)	0.376	
MSP5	4.70	-1.92e-6 (-5.28e-6-1.43e-6)	0.258	0.34 (0.049-0.64)	0.023	
RIPR	3.66	-2.8e-6 (-7.78e-6-2.18e-6)	0.267	0.25 (-0.015-0.51)	0.065	
RBP2b ₁₆₁₋₁₄₅₄	3.00	1.59e-6 (-3.74e-6 - 6.95e-6)	0.557	0.073 (-0.18-0.32)	0.56	
Pv-fam-a (PVX_112670)	2.76	9.23e-7 (-1.62e-6-3.46e-6)	0.473	-0.036 (24-0.17)	0.724	
RBP2a	2.45	-2.78e-6 (-5.99e-6-4.35e-7)	0.09	-0.02 (-2.2-0.18)	0.842	
MSP3b	1.93	7.7e-7 (-1.16e-6 - 2.7e-6)	0.432	0.26 (0.053-0.46)	0.014	
MSP3a	1.92	-7.73e-7 (-3.5e-6-1.95e-6)	0.575	0.28 (0.047-0.52)	0.019	
EBP	1.33	-2.02e-6 (-4.83e-6-7.94e-7)	0.158	0.057 (-0.16-0.27)	0.603	
DBPII AH	1.31	-3.6e-9 (-5.52e-66.03e-				
		7)	0.015	0.178 (0.005-0.35)	0.044	
S16	1.18	8.4e-7 (-3.57e-6-5.25e-6)	0.707	0.23 (-0.035-0.49)	0.089	
Hypothetical	1.16	-7.69e-7 (-4.23e-6-2.69e-6)	0.661	0.18 (-0.067-0.430	0.152	
DBPII Sal1	1.02	-2.13e-6 (-5.29e-6-1.03e-6)	0.185	0.17 (-0.022-0.36)	0.082	
TRAP	0.90	3.31e-7 (-3.95e-6 - 4.61e-6)	0.878	0.11 (-0.096-0.31)	0.297	
MSP7L	0.78	-8.79e-7 (-3.09e-6-1.34e-6)	0.434	0.16 (-0.077-0.40)	0.185	
MSP7F	0.78	4.55e-6 (1.29e-6-7.82e-6)	0.007	0.16 (-0.093-0.41)	0.217	
RBP2b ₁₉₈₆₋₂₆₅₃	0.44	2.67e-6 (-1.06e-6 - 6.4e-6)	0.159	0.20 (-0.055-0.45)	0.125	